SCHEMBL892055

SCHEMBL892055

C[C@H](C(=O)O)c1ccc(O)cc1

nearest known ligand 0.63

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PTGS2 P35354 10/20 0.63
PTGS1 P23219 8/20 0.59
AKR1C3 P42330 7/20 0.59
AKR1C2 P52895 6/20 0.59
CYP2C9 P11712 5/20 0.59
LMNA P02545 3/20 0.59
CXCR1 P25024 2/20 0.59
CXCR2 P25025 2/20 0.59
ESR1 P03372 2/20 0.59
SLC22A6 Q4U2R8 2/20 0.59
TSHR P16473 2/20 0.59
ALB P02768 1/20 0.59
ALOX5 P09917 1/20 0.59
RARB P10826 1/20 0.59
ADRB3 P13945 1/20 0.59
NFKB1 P19838 1/20 0.59
HTR2A P28223 1/20 0.59
NR1I3 Q14994 1/20 0.59
CXCL8 P10145 1/20 0.59
BLM P54132 1/20 0.59

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL288003 1.00 PTGS2 (0.63) PTGS2PTGS1AKR1C3AKR1C2CYP2C9
SCHEMBL1345582 1.00 PTGS2 (0.63) PTGS2PTGS1AKR1C3AKR1C2CYP2C9
SCHEMBL9232479 0.98 PTGS2 (0.61) PTGS2PTGS1AKR1C3AKR1C2CYP2C9
Hydrochloric Acid SCHEMBL28716582 0.98 PTGS2 (0.61) PTGS2PTGS1AKR1C3AKR1C2CYP2C9
SCHEMBL9232475 0.98 PTGS2 (0.61) PTGS2PTGS1AKR1C3AKR1C2CYP2C9
SCHEMBL9234136 0.98 PTGS2 (0.61) PTGS2PTGS1AKR1C3AKR1C2CYP2C9
SCHEMBL1678786 0.94 PTGS2 (0.74) PTGS2PTGS1AKR1C3AKR1C2CYP2C9
Butane SCHEMBL27363299 0.92 PTGS2 (0.56) PTGS2PTGS1AKR1C3AKR1C2CYP2C9
SCHEMBL59197 0.90 PTGS2 (0.74) PTGS2PTGS1AKR1C3AKR1C2CYP2C9
SCHEMBL4255166 0.90 LMNA (0.58) PTGS2PTGS1AKR1C3AKR1C2CYP2C9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 42 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-107988307-A The method that enzymatic stereoselectivity splits 2- (4- hydroxy phenyls) propionic acid enantiomer 湖南理工学院 2018-05-04 CN claimed
US-20240025849-A1 INHIBITORS OF NO PRODUCTION CHARITÉ - UNIVERSITÄTSMEDIZIN BERLIN (DE) 2024-01-25 US disclosed
EP-3842420-B1 HETEROARYL INHIBITORS OF PDE4 TETRA DISCOVERY PARTNERS LLC (US) 2022-12-07 EP disclosed
US-20220218664-A1 DRUG AND METHOD FOR TREATING OR PREVENTING COMPLICATIONS FROM DIABETES, USING SAID DRUG SHOWA UNIVERSITY (JP) 2022-07-14 US disclosed
US-10329575-B2 Regulatory sequence for plants CERES, INC. (US) 2019-06-25 US disclosed
US-20180223303-A1 SEQUENCE-DETERMINED DNA FRAGMENTS AND CORRESPONDING POLYPEPTIDES ENCODED THEREBY CERES INC (US) 2018-08-09 US disclosed
CN-107988307-A The method that enzymatic stereoselectivity splits 2- (4- hydroxy phenyls) propionic acid enantiomer 湖南理工学院 2018-05-04 CN disclosed
US-20170342094-A1 HETEROARYL INHIBITORS OF PDE4 Tetra Discovery Partners, LLC 2017-11-30 US disclosed
US-9777024-B2 Heteroaryl inhibitors of PDE4 Tetra Discovery Partners, LLC (US) 2017-10-03 US disclosed
US-20170037426-A1 Sequence-determined DNA fragments and corresponding polypeptides encoded thereby ALEXANDROV NICKOLAI (US) 2017-02-09 US disclosed
EP-1455773-B1 2-ARYL-PROPIONIC ACIDS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM DOMPE PHA R MA SPA RES & MFG (IT) 2009-11-04 EP disclosed
US-20090265815-A1 Sequence-determined DNA fragments and corresponding polypeptides encoded therapy ALEXANDROV NICKOLAI 2009-10-22 US disclosed
US-20070214517-A1 Sequence-determined DNA fragments and corresponding polypeptides encoded thereby CERES, INC. (US) 2007-09-13 US disclosed
US-20060150283-A1 Sequence-determined DNA fragments and corresponding polypeptides encoded thereby ALEXANDROV NICKOLAI 2006-07-06 US disclosed
US-20060048240-A1 Sequence-determined DNA fragments and corresponding polypeptides encoded thereby ALEXANDROV NICKOLAI 2006-03-02 US disclosed
CN-1612729-A 2-Aryl-propionic acids and pharmaceutical compositions containing them DOMPAY CO LTD (IT) 2005-05-04 CN disclosed
US-20050038119-A1 2-Aryl-propionic acids and pharmaceutical compositions containing them DOMPÉ FARMACEUTICI S.P.A. (IT) 2005-02-17 US disclosed
EP-1455773-A1 2-ARYL-PROPIONIC ACIDS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM Dompé S.P.A. (IT) 2004-09-15 EP disclosed
WO-2003043625-A1 2-ARYL-PROPIONIC ACIDS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM DOMPE S.P.A. (IT) 2003-05-30 WO disclosed
EP-0673924-A1 PROPIONIC ACID DERIVATIVE TEIKOKU CHEMICAL INDUSTRY CO., LTD. (JP) 1995-09-27 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170037426-A1 Sequence-determined DNA fragments and corresponding polypeptides encoded thereby RNGTT, CPSF1, CPSF6 PTGS2 4377/4885PTGS1 4544/4885AKR1C3 3032/4885
US-20070214517-A1 Sequence-determined DNA fragments and corresponding polypeptides encoded thereby RNGTT, CPSF1, CPSF6 PTGS2 4377/4885PTGS1 4544/4885AKR1C3 3032/4885
US-20220218664-A1 DRUG AND METHOD FOR TREATING OR PREVENTING COMPLICATIONS FROM DIABETES, USING SAID DRUG SLC5A2, SLC5A1, IAPP PTGS2 142/4885PTGS1 74/4885AKR1C3 1134/4885
US-20240025849-A1 INHIBITORS OF NO PRODUCTION NOS2, NOS1, NOS3 PTGS2 12/4885PTGS1 9/4885AKR1C3 1072/4885
US-20170342094-A1 HETEROARYL INHIBITORS OF PDE4 PDE4A, PDE4B, PDE4C PTGS2 75/4885PTGS1 48/4885AKR1C3 842/4885
US-20060048240-A1 Sequence-determined DNA fragments and corresponding polypeptides encoded thereby RNGTT, CPSF1, CPSF6 PTGS2 4377/4885PTGS1 4544/4885AKR1C3 3032/4885
US-20050038119-A1 2-Aryl-propionic acids and pharmaceutical compositions containing them CXCR2, FPR1, CCR2 PTGS2 99/4885PTGS1 88/4885AKR1C3 767/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.